Xarelto Liability Suit: Is Label 'Silent' About Increased Bleeding Risk?

Even after multiple bellweather wins, Janssen and Bayer still face claims they did not warn doctors about concomitant use with Plavix and aspirin; as case begins in Philadelphia, plaintiff's attorney tells jury the firms were 'silent,' while defense points to doctors' testimony that a different warning would not have changed their prescribing.

court house

PHILADELPHIA – Plaintiff's lawyers hammered one message to the jury in the opening of a Xarelto (rivaroxaban) product liability trial on April 6: Bayer AG and Janssen Pharmaceuticals Inc. were silent about the increased risk of bleeding in those who take the drug with Plavix (clopidogrel) and aspirin, two other blood thinners.

Before beginning his opening statement, Brian Barr, of Levin Papantonio, placed an easel with a large pad of paper in...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Drug Safety

More from Pink Sheet